Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Lower levels of placental growth hormone in early pregnancy in women with type 1 diabetes and large for gestational age infants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Insulin-like growth factor I enhances collagen synthesis in engineered human tendon tissue

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Positive associations between serum levels of IGF-I and subcutaneous fat depots in young men. The Odense Androgen Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The insulin like growth factor system in cirrhosis. Relation to changes in body composition following adrenoreceptor blockade

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Brain tumours in children and adolescents may affect the circadian rhythm and quality of life

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Increase of Ki-67 index and influence on mortality in patients with neuroendocrine neoplasms

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Somatotropinomas have unique "fingerprints" of somatostatin receptor (sst) expression, which are targets in treatment of acromegaly with somatostatin analogues (SSAs). However, a significant expression of sst is not always related to the biochemical response to SSAs. Headache is a common complaint in acromegaly and considered a clinical marker of disease activity. SSAs are reported to have an own analgesic effect, but the sst involved are unknown.

PATIENTS AND METHODS: We investigated sst expression in two acromegalic patients with severe headache and no biochemical effects of octreotide, but a good response to pasireotide. We searched the literature for determinants of biochemical and analgesic effects of SSAs in somatotropinomas.

RESULTS: Case 1 had no biochemical or analgesic effects of octreotide, a semi-selective SSA, but a rapid and significant effect of pasireotide, a pan-SSA. Case 2 demonstrated discordance between analgesic and biochemical effects of octreotide, in that headache disappeared, but without biochemical improvement. In contrast, pasireotide normalized insulin-like growth factor 1. Both adenomas were sparsely granulated and had strong membranous expressions of sst2a in 50-75% and sst5 in 75-100% of tumor cells. The truncated sst5 variant TMD4 (sst5TMD4) showed expression in 20-57% of tumor cells.

CONCLUSIONS: A poor biochemical response to octreotide may be associated with tumor expression of a truncated sst5 variant, despite abundant sst2a expression, suggesting an influence from variant sst5 on common sst signaling pathways. Furthermore, unrelated analgesic and biochemical effects of SSAs supported a complex pathogenesis of acromegaly-associated headache. Finally, assessment of truncated sst5 in addition to full length sst could be important for a choice of postoperative SSA treatment in somatotropinomas.

OriginalsprogEngelsk
TidsskriftGrowth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
Vol/bind25
Udgave nummer5
Sider (fra-til)262-7
Antal sider6
ISSN1096-6374
DOI
StatusUdgivet - okt. 2015

ID: 46005401